<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Insight Molecular Diagnostics Inc. — News on 6ix</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc</link>
<description>Latest news and press releases for Insight Molecular Diagnostics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/insight-molecular-diagnostics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d75e0351cc36e475338e20.webp</url>
<title>Insight Molecular Diagnostics Inc.</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc</link>
</image>
<item>
<title>IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-submits-graftassuredx-for-fda-review-and-reports-q4-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-submits-graftassuredx-for-fda-review-and-reports-q4-2025-results</guid>
<pubDate>Thu, 26 Mar 2026 20:05:00 GMT</pubDate>
<description>Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to a leading centralized transplant rejection testExpect U.K. CE marking via self-certification in Q2 2026Completed $26 million financing in February; funds intended to support expansion into heart transplantation market while also commercializing testing for kidney NASHVILLE, Tenn.,</description>
</item>
<item>
<title>iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-release-fourth-quarter-2025-results-on-march-26-2026-and-attend-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-release-fourth-quarter-2025-results-on-march-26-2026-and-attend-needham-virtual-healthcare-conference</guid>
<pubDate>Fri, 20 Mar 2026 12:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q4 2025 Earn</description>
</item>
<item>
<title>Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/second-study-affirms-superiority-of-imdx-graftassure-assays-proprietary-dd-cfdna-combination-model-score-53</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/second-study-affirms-superiority-of-imdx-graftassure-assays-proprietary-dd-cfdna-combination-model-score-53</guid>
<pubDate>Fri, 13 Mar 2026 12:00:00 GMT</pubDate>
<description>New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary “Combination Model” score outperformed percentage-only measures of dd-cfDNAReinforces data presented at World Transplant Congress in 2025 NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new peer-reviewed study demonstrating the potential superiority of the company’s flagship</description>
</item>
<item>
<title>Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/insight-molecular-diagnostics-completes-key-milestones-advancing-graftassuredx-toward-fda-submission</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/insight-molecular-diagnostics-completes-key-milestones-advancing-graftassuredx-toward-fda-submission</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White HealthSufficient clinical samples collected to</description>
</item>
<item>
<title>iMDx Announces $26.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-announces-dollar260-million-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-announces-dollar260-million-registered-direct-offering</guid>
<pubDate>Wed, 11 Feb 2026 05:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has</description>
</item>
<item>
<title>IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-supports-ast-and-ashi-star-working-groups-call-for-decentralized-transplant-monitoring</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-supports-ast-and-ashi-star-working-groups-call-for-decentralized-transplant-monitoring</guid>
<pubDate>Tue, 13 Jan 2026 14:00:00 GMT</pubDate>
<description>American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx’s flagship GraftAssureTM family of assays NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today congratulated the STAR working group on its position paper in the American Journal of Transplantation in recognizing the need for decentralized organ health testing in the global tra</description>
</item>
<item>
<title>iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-announces-jpm-week-and-btig-snowbird-conference-participation</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-announces-jpm-week-and-btig-snowbird-conference-participation</guid>
<pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference. LifeSci Advisors 15th Annual Corporate Access Event Date: Monday, January 12thLocation: The Beacon Grand, San Francisco, Calif.Format: One-on-one meetings with management Additional “</description>
</item>
<item>
<title>iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-welcome-industry-veteran-as-vice-president-of-medical-affairs-to-prepare-for-commercial-transplant-assay-launch</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-welcome-industry-veteran-as-vice-president-of-medical-affairs-to-prepare-for-commercial-transplant-assay-launch</guid>
<pubDate>Tue, 06 Jan 2026 13:00:00 GMT</pubDate>
<description>Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experience spanning clinical practic</description>
</item>
<item>
<title>iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-prepares-for-us-commercial-launch-of-graftassuredx-as-clinical-trial-nears-completion</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-prepares-for-us-commercial-launch-of-graftassuredx-as-clinical-trial-nears-completion</guid>
<pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
<description>GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx™ FDA IVD approval application 95% complete at year-end; expect full submission in coming weeksAccelerating planned UK CE mark and EU IVDR submission to first half 2026, following successful TÜV SÜD ISO 13485 stage 1 & 2 audit completions in Q4 2025Strong engagement from clinical community on GraftAssureCore™ kidney registry with 17 U.S. transpla</description>
</item>
<item>
<title>IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-reports-q3-2025-results-and-progress-toward-2026-commercial-launch</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-reports-q3-2025-results-and-progress-toward-2026-commercial-launch</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology</description>
</item>
<item>
<title>iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-release-third-quarter-2025-results-on-november-10-and-attend-stephens-annual-investment-conference-the-following-week</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-release-third-quarter-2025-results-on-november-10-and-attend-stephens-annual-investment-conference-the-following-week</guid>
<pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q3 2025 Earni</description>
</item>
<item>
<title>iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-welcomes-new-vp-marketing-to-prepare-for-commercial-transplant-assay-launch</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-welcomes-new-vp-marketing-to-prepare-for-commercial-transplant-assay-launch</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future productsBrings 25 years of experience driving new product</description>
</item>
<item>
<title>iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-reports-kidney-transplant-patient-achieved-immune-reset-with-novel-therapy-and-graftassure-monitoring</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-reports-kidney-transplant-patient-achieved-immune-reset-with-novel-therapy-and-graftassure-monitoring</guid>
<pubDate>Mon, 06 Oct 2025 11:15:00 GMT</pubDate>
<description>American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid overtreatment and preserve patient’s immune systemAs transplant care evolves to include novel therapies, the need for ongoing molecular diagnostic monitoring should continue to grow NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMD</description>
</item>
<item>
<title>Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/insight-molecular-diagnostics-to-showcase-leadership-in-kidney-transplant-management-at-conferences-in-singapore-and-orlando</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/insight-molecular-diagnostics-to-showcase-leadership-in-kidney-transplant-management-at-conferences-in-singapore-and-orlando</guid>
<pubDate>Wed, 24 Sep 2025 11:05:00 GMT</pubDate>
<description>IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ at symposium on Thursday, October 9th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced attendance at two key industry c</description>
</item>
<item>
<title>IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-enrolls-first-patient-in-graftassuredx-clinical-trial-and-welcomes-new-hospital-participants</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-enrolls-first-patient-in-graftassuredx-clinical-trial-and-welcomes-new-hospital-participants</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>iMDx’s ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of</description>
</item>
<item>
<title>Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/insight-molecular-diagnostics-announces-positive-strategic-update-and-novel-registry-database</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/insight-molecular-diagnostics-announces-positive-strategic-update-and-novel-registry-database</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>5,000-participant, multi-center registry supported by iMDx’s central lab and transplant center partnersNew hospital-based data seeks to further differentiate</description>
</item>
<item>
<title>iMDx to Participate in NYC Investment Conferences September 8 - 11</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-participate-in-nyc-investment-conferences-september-8-11</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-participate-in-nyc-investment-conferences-september-8-11</guid>
<pubDate>Tue, 26 Aug 2025 20:05:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced participation in investor conferences hosted by both H.C. Wainwright and Lake Street Capital Markets. Information for each can be found below: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8 – 9, 2025Location: In-person at the Lotte New York Palace Hotel and virtual Format: Company presentation on Monday, September 8 at 5:00 pm ET, and</description>
</item>
<item>
<title>IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-cfo-andrea-james-featured-in-empowered-patient-podcast-on-democratizing-molecular-diagnostics</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-cfo-andrea-james-featured-in-empowered-patient-podcast-on-democratizing-molecular-diagnostics</guid>
<pubDate>Mon, 25 Aug 2025 13:15:00 GMT</pubDate>
<description>BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The Empowered Patient Podcast with Karen Jagoda recently featured Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) (Nasdaq: IMDX), in an episode on “Democratizing Molecular Diagnostics: Transforming Transplant Success.” Andrea James, Chief Financial Officer of Insight Molecular Diagnostics, Inc. (iMDx) In the episode, James discussed iMDx’s mission, the company’s focus on transplant diagnostics, and its strategy to brin</description>
</item>
<item>
<title>IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-reports-q2-2025-results-and-momentum-toward-graftassuredx-launch</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-reports-q2-2025-results-and-momentum-toward-graftassuredx-launch</guid>
<pubDate>Mon, 11 Aug 2025 20:05:00 GMT</pubDate>
<description>Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits; began shipping second generation kits in June NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results: Fellow shareholders, We are closer than we</description>
</item>
<item>
<title>iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference</title>
<link>https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-release-second-quarter-2025-results-on-august-11-2025-and-attend-needham-virtual-medtech-and-diagnostics-conference</link>
<guid isPermaLink="true">https://6ix.com/company/insight-molecular-diagnostics-inc/news/imdx-to-release-second-quarter-2025-results-on-august-11-2025-and-attend-needham-virtual-medtech-and-diagnostics-conference</guid>
<pubDate>Mon, 04 Aug 2025 20:05:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q2 2025 Earnings W</description>
</item>
</channel>
</rss>